Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Novartis AGNYSE: NVS

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables growth accelerates

Q2 FY2026 accounts receivables of $255.64M (cash outflow) rose 53.1% year over year, ahead of the -6.6% change in trailing-twelve-month accounts receivables. Sequentially, it fell 49.3% from the prior quarter. Over 3 fiscal years it compounded at +41.7% a year.

Context

  • Accounts receivables amounted to 2.1% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Accounts receivables grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +53.1% holds above the trailing-twelve-month pace of -6.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$255.64M-49.3% QoQ
Last fiscal yearDec 2025
-$1.13B+21.3% YoY
LTMJun 2026
-$672.78M-6.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.1%——
1 year+21.3%——
3-year CAGR+41.7%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(1.13B) USD
Year-over-year change
-21.3%

Accounts Receivables vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.6% is the 4th highest of 5, against a peer median of +35.3%.
  • Accounts receivables amounts to 1.2% of revenue for NVS, versus a peer median of 0.9%.
NVS Competitors
Accounts Receivables for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.37B USD+3.7%+11.4%1.4%
ABBVAbbVie Inc.LTM Jun 2026$1.28B USD+66.8%+0.8%2.0%
MRKMerck & Co., Inc.LTM Jun 2026$1.09B USD—+19.2%1.6%
SNYSanofiLTM Jun 2026€753.5M EUR—+39.5%1.5%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$678M USD+102.4%-23.7%1.4%
NVSNovartis AGLTM Jun 2026$672.78M USD-6.6%+41.7%1.2%
GILDGilead Sciences, Inc.LTM Jun 2026$154M USD-833.3%-3.3%0.5%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding NVS) —+35.3%+6.1%0.9%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.